Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Over the last decade, pioneering liver‐directed gene therapy trials for haemophilia B have achieved sustained clinical improvement after a single systemic injection of adeno‐associated virus (AAV) derived vectors encoding the human factor IX cDNA. These trials demonstrate the potential of AAV technology to provide long‐lasting clinical benefit in the treatment of monogenic liver disorders. Indeed, with more than ten ongoing or planned clinical trials for haemophilia A and B and dozens of trials planned for other inherited genetic/metabolic liver diseases, clinical translation is expanding rapidly. Gene therapy is likely to become an option for routine care of a subset of severe inherited genetic/metabolic liver diseases in the relatively near term. In this review, we aim to summarise the milestones in the development of gene therapy, present the different vector tools and their clinical applications for liver‐directed gene therapy. AAV‐derived vectors are emerging as the leading candidates for clinical translation of gene delivery to the liver. Therefore, we focus on clinical applications of AAV vectors in providing the most recent update on clinical outcomes of completed and ongoing gene therapy trials and comment on the current challenges that the field is facing for large‐scale clinical translation. There is clearly an urgent need for more efficient therapies in many severe monogenic liver disorders, which will require careful risk‐benefit analysis for each indication, especially in paediatrics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“Recent clinical successes in various inherited orphan diseases such as Leber’s congenital amaurosis (Bainbridge et al 2008; Cideciyan et al 2008; Maguire et al 2008), X-linked adrenoleukodystrophy (Cartier et al 2009), metachromatic leukodystrophy (Biffi et al 2013) and haemophilia B (Nathwani et…”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Recent clinical successes in various inherited orphan diseases such as Leber’s congenital amaurosis (Bainbridge et al 2008; Cideciyan et al 2008; Maguire et al 2008), X-linked adrenoleukodystrophy (Cartier et al 2009), metachromatic leukodystrophy (Biffi et al 2013) and haemophilia B (Nathwani et…”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Gene therapy - promises, problems and prospects
Verma, I. M., & Somia, N. (1997) · Nature · doi:10.1038/38410 · Cited by 1,681
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 2×
“…diseases such as Leber’s congenital amaurosis (Bainbridge et al 2008; Cideciyan et al 2008; Maguire et al 2008), X-linked adrenoleukodystrophy (Cartier et al 2009), metachromatic leukodystrophy (Biffi et al 2013) and haemophilia B (Nathwani et al 2011) and the first market authorisation…”
BackgroundLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 7×
“MHC1: major histocompatibility complex I might be explained by a less efficient liver transduction mediated by AAV5 relative to AAV8 and a reduced expression of the episomal transgene compared to the endogenous gene of interest (Baruteau et al 2017).”
BackgroundInfluentialDevelopment of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 1×
“To improve safety, self-inactivating (SIN) vectors have been developed in which LTR enhancer/promoter elements in the U3 region have been deleted (Miyoshi et al 1998; Zufferey et al 1998).”
MethodLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061 · cited 1×
“These Baccelerated evolution^ libraries are generated using strategies such as error-prone PCR (Kotterman and Schaffer 2014; Deverman et al 2016) and Bcapsid shuffling^ with random cut-paste sequences of wild type cap genes (Kay 2011; Louis Jeune et al 2013; Choudhury et al 2016).”
MethodBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 3×
“…delivery provides similar transduction compared to intrahepatic or intraportal routes for AAV vectors (Sarkar et al 2006; Nathwani et al 2007); ii) higher doses of vector achieve greater transduction, but may generate more severe immune responses (Raper et al 2003; Mingozzi and High 2013).”
BackgroundRobust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 1×
“These Baccelerated evolution^ libraries are generated using strategies such as error-prone PCR (Kotterman and Schaffer 2014; Deverman et al 2016) and Bcapsid shuffling^ with random cut-paste sequences of wild type cap genes (Kay 2011; Louis Jeune et al 2013; Choudhury et al 2016).”
MethodAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 3×
“Unlike research animals, humans are exposed to wild type AAV infections generating anti-AAV memory T cells, which are reactivated at the time of vector exposure (Mingozzi et al 2007).”
BackgroundAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 2×
“This risk increased with the enhancer/promoter activity, younger age at time of injection and vector dose (Donsante et al 2007; Chandler et al 2015; Chandler et al 2017).”
BackgroundWirth, T., Parker, N., & Ylä-Herttuala, S. (2013) · Gene · doi:10.1016/j.gene.2013.03.137 · Cited by 607
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 1×
“In these experiments, two AAV vectors were injected simultaneously, one of which encoded the transgene and the other the enzymatic system for integration or site specific cutting by Piggybac transposase (Cunningham et al 2015) and CRISPR-Cas9 (Yang et al 2016), respectively.”
MethodAdenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
An essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 1×
“As a consequence the packaging size of the transgene cassette in scAAV is reduced by half (McCarty 2008).”
BackgroundRecurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“…of the integrase protein to generate non- integrating or integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and…”
BackgroundSelection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450 · cited 3×
“This approach is paying off by generating re-engineered AAV variants with increased transduction efficiency in primary human hepatocytes (Lisowski et al 2014).”
BackgroundSelf-citationIntegration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403 · cited 3×
“Integration occurred in the Rian hotspot, a rodent-specific locus absent in other vertebrate genomes (Chandler et al 2015).”
BackgroundPre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358 · cited 3×
“These Baccelerated evolution^ libraries are generated using strategies such as error-prone PCR (Kotterman and Schaffer 2014; Deverman et al 2016) and Bcapsid shuffling^ with random cut-paste sequences of wild type cap genes (Kay 2011; Louis Jeune et al 2013; Choudhury et al 2016).”
BackgroundMethodAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“Thereafter, seroprevalence remains negligible until 3 years of age after which the seroconversion rate progressively increases until adulthood (Calcedo et al 2011; Li et al 2012).”
BackgroundNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationFlotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
A robust system for production of minicircle DNA vectors
Kay, M. A., He, C.-Y., & Chen, Z.-Y. (2010) · Nature Biotechnology · doi:10.1038/nbt.1708 · Cited by 329 · cited 1×
“These approaches allow easy production of therapeutic material with a good safety profile and capable of eliciting longlasting transgene expression in post-mitotic tissues (Wolff and Budker 2005; Kay et al 2010).”
BackgroundBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327 · cited 1×
“In both trials, minor side effects and a seroconversion against AAV1 were observed (Brantly et al 2009; Flotte et al 2011).”
BackgroundImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency
Wilson, J. M. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.016 · Cited by 299
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286 · cited 1×
“The industry is progressively taking up the gauntlet and developing improved and innovative methods for vector production in larger bioreactors with optimised reagents, purification techniques and packaging cell lines (Clement and Grieger 2016; Grieger et al 2016).”
MethodLiver zonation: Novel aspects of its regulation and its impact on homeostasis
Gebhardt, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8491 · Cited by 275
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262 · cited 2×
“The overlapping approach uses vectors A and B, which display a homology sequence to promote intermolecular homologous recombination (Duan et al 2001; Koo et al 2014).”
BackgroundMethodPhilippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · cited 1×
“…relies on the mutation of the integrase protein to generate non- integrating or integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et…”
BackgroundHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 1×
“Whatever the viral vector considered, immune responses share various similarities, and must always be carefully considered (Bessis et al 2004; Tang et al 2006; Annoni et al 2013; Calcedo and Wilson 2013; BasnerTschakarjan and Mingozzi 2014).”
BackgroundBreous, E., Somanathan, S., Vandenberghe, L. H., & Wilson, J. M. (2009) · Hepatology · doi:10.1002/hep.23043 · Cited by 237 · cited 1×
“…familial hypercholesterolaemia caused by mutations in the LDLR (Nomura et al 2004) and ApoE genes (Belalcazar et al 2003) in rodents, haemophilia A (Brown et al 2004; McCormack et al 2006) and B (Ehrhardt et al 2003; Brunetti-Pierri et al 2005), glycogen storage disease type 1 (Crane et al 2012)…”
BackgroundLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206 · cited 1×
“These include plasmapheresis (Monteilhet et al 2011; Chicoine et al 2014), monoclonal antiCD20 antibody (rituximab) (Mingozzi et al 2013; Corti et al 2014), non-depleting antiCD4 antibody (McIntosh et al 2012), sirolimus (Corti et al 2014), cyclosporine A (McIntosh et al 2012; Mingozzi et al 2012),…”
BackgroundPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 1×
“The following examples demonstrate why animal experiments provide limited value for predicting effects in human trials: – T-cell mediated cytotoxicity observed in the first haemophilia B trial was not predicted by experiments in mice, dogs or non-human primates (Pien et al 2009).”
BackgroundTransient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192
Lessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189 · cited 2×
“This drug has been in development for 8 years, with the initial developer going bankrupt and a currently proposed market cost of $1.2 million per patient (Bryant et al 2013).”
BackgroundInfluentialStable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · cited 1×
“…integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and phenotype correction in mice with haemophilia B (Suwanmanee et al 2014).”
BackgroundSelf-citationLiver-directed lentiviral gene therapy in a dog model of hemophilia B
Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1405 · Cited by 158 · cited 1×
“…development: i) systemic lentiviral-mediated liver-restricted gene therapy in a dog model of haemophilia B, which showed long-term efficacy, induction of liver tolerogenic properties in stimulating CD4+CD25+FoxP3+ regulatory T cells and no evidence of genotoxicity in mice (Cantore et al 2015).”
BackgroundAdeno-Associated Virus Gene Therapy for Liver Disease
Kattenhorn, L. M., Tipper, C. H., Stoica, L., Geraghty, D. S., Wright, T. L., Clark, K. R., & Wadsworth, S. C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.160 · Cited by 138
Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125 · cited 2×
“…by Uniqure (Miesbach et al 2016) and the DTX-101 sponsored by Dimension Therapeutics (http://dimensiontx.com) to 20–44% in the high-dose cohort of the BAX 335 trial sponsored by Shire (Monahan et al 2015) and in the SPK-9001 trial sponsored by Spark Therapeutics/Pfizer (George et al 2016).”
Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid
Vercauteren, K., Hoffman, B. E., Zolotukhin, I., Keeler, G. D., Xiao, J. W., Basner-Tschakarjan, E., High, K. A., Ertl, H. C., Rice, C. M., Srivastava, A., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.61 · Cited by 114 · cited 3×
“For example, AAV3B uses the human hepatocyte growth factor (hHGF) receptor, which restricts transduction to primates and especially to the liver (Vercauteren et al 2016).”
BackgroundMingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112 · cited 1×
“These include plasmapheresis (Monteilhet et al 2011; Chicoine et al 2014), monoclonal antiCD20 antibody (rituximab) (Mingozzi et al 2013; Corti et al 2014), non-depleting antiCD4 antibody (McIntosh et al 2012), sirolimus (Corti et al 2014), cyclosporine A (McIntosh et al 2012; Mingozzi et al 2012),…”
BackgroundPatient monitoring and follow‐up in lentiviral clinical trials
McGarrity, G. J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R. N., Kinder, C., Zolopa, A., Binder‐Scholl, G., et al. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2691 · Cited by 109 · cited 1×
“So far, more than 125 patients over 14 years have been treated with haematopoietic stem cells or T cells transduced by lentiviral vectors with no oncogenic event reported (Cartier et al 2009; Biffi et al 2013; McGarrity et al 2013; Booth et al 2016).”
BackgroundEarley, L. F., Powers, J. M., Adachi, K., Baumgart, J. T., Meyer, N. L., Xie, Q., Chapman, M. S., & Nakai, H. (2017) · Journal of Virology · doi:10.1128/jvi.01980-16 · Cited by 108 · cited 1×
“Some, but not all, AAV capsid serotypes (Earley et al 2017) require expression of an assembly-activating protein (AAP) encoded by an alternative reading frame of the Cap gene and providing scaffolding activity (Naumer et al 2012).”
BackgroundKoo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104 · cited 1×
“The overlapping approach uses vectors A and B, which display a homology sequence to promote intermolecular homologous recombination (Duan et al 2001; Koo et al 2014).”
MethodRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101 · cited 1×
“…integration-deficient lentiviral vectors (Nightingale et al 2006; Philippe et al 2006; Yanez-Munoz et al 2006), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al 2007; Rahim et al 2009) and phenotype correction in mice with haemophilia B (Suwanmanee et al 2014).”
BackgroundSelf-citationProperties of the Adeno-Associated Virus Assembly-Activating Protein
Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N. E., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.01675-12 · Cited by 97 · cited 1×
“Some, but not all, AAV capsid serotypes (Earley et al 2017) require expression of an assembly-activating protein (AAP) encoded by an alternative reading frame of the Cap gene and providing scaffolding activity (Naumer et al 2012).”
BackgroundThwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76 · cited 20×
“To achieve adequate control of severe hyperammonaemia in the OTCDmouse model, therefore, requires a much higher than expected dose of AAV2/8 vector carrying OTC transgene, which might be explained by the non-physiological pattern of liver transduction (Cunningham et al 2011).”
ResultInfluentialMcIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70 · cited 2×
“…et al 2011; Chicoine et al 2014), monoclonal antiCD20 antibody (rituximab) (Mingozzi et al 2013; Corti et al 2014), non-depleting antiCD4 antibody (McIntosh et al 2012), sirolimus (Corti et al 2014), cyclosporine A (McIntosh et al 2012; Mingozzi et al 2012), tacrolimus with mycophenolate mofetil…”
BackgroundStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
Early clinical data raise the bar for hemophilia gene therapies
Dolgin, E. (2016) · Nature Biotechnology · doi:10.1038/nbt1016-999 · Cited by 16 · cited 2×
“A lentiviral vector is currently in preclinical development for haemophilia B (Dolgin 2016).”
BackgroundMethod
Cited by
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Self-citationGene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903
Self-citationLipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation
Lei, S., Zhang, X., Men, K., Gao, Y., Yang, X., Wu, S., Duan, X., Wei, Y., & Tong, R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00451 · Cited by 83
Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort
Perocheau, D. P., Cunningham, S. C., Lee, J., Antinao Diaz, J., Waddington, S. N., Gilmour, K., Eaglestone, S., Lisowski, L., Thrasher, A. J., Alexander, I. E., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.098 · Cited by 81
Self-citation
Metadata
- Authors
- Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2017-05-31
- Volume
- 40
- Issue
- 4
- Pages
- 497-517
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2618545704
- Cited by
- 110
- References
- 67
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.